Scholarlink

<p>Metabolic dysfunction-associated steatotic liver disease (MASLD), the most prevalent cause of chronic liver disease worldwide, currently lacks precision medicine treatments. SLCO4C1 acts as a transporter for endogenous compounds and xenobiotics. This study aims to investigate whether SLCO4C1 plays a regulatory role in MASLD pathogenesis and to elucidate the underlying mechanisms. Using human, mouse and cellular models, we found that hepatocyte SLCO4C1 is upregulated in MASLD patients, where it serves as a key cAMP transporter dependent on Gln463, suppressing lipogenesis through the PKA-CREB-SREBP1 pathway. Hepatocyte-specific delivery of <i>Slco4c1</i> via AAV8-TBG increased hepatic cAMP levels, alleviating steatosis, inflammation, and fibrosis in MASLD male mice. Similarly, forskolin, an adenylyl cyclase activator that elevates cAMP, alleviated MASLD progression, underscoring the translational potential of targeting the SLCO4C1-cAMP signaling axis. Mechanistically, during MASLD progression, FGF21 upregulates hepatic Slco4c1 expression through activating ERK/MAPK signaling, which induces EGR1 to directly bind the <i>Slco4c1</i> promoter, increasing intrahepatic cAMP levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月13日

查看全文
  • Xiaojia Huang,
  • Sen Liang,
  • Nan Zhao,
  • Jingjing Ding,
  • Siyi Jiang,
  • Changpei Gan,
  • Huayu Zhang,
  • Lei Zuo,
  • Yangyang Li,
  • Xiaoxun Zhang,
  • Jingdong Zhao,
  • Zhixian Zhu,
  • Liangjun Zhang,
  • Ling Li,
  • Ying Cheng,
  • Xiaoman Xie,
  • Qian Yuan,
  • Xiaolan Yang,
  • Jiangchuan Tian,
  • Mindian Li,
  • Minghua Zheng,
  • Christopher D. Byme,
  • Giovanni Targher,
  • Xinshou Ouyang,
  • Qiong Pan,
  • Xiaolei Hu,
  • Chuanzheng Sun,
  • Huaizheng Liu,
  • Jin Chai

摘要

Metabolic dysfunction-associated steatotic liver disease (MASLD), the most prevalent cause of chronic liver disease worldwide, currently lacks precision medicine treatments. SLCO4C1 acts as a transporter for endogenous compounds and xenobiotics. This study aims to investigate whether SLCO4C1 plays a regulatory role in MASLD pathogenesis and to elucidate the underlying mechanisms. Using human, mouse and cellular models, we found that hepatocyte SLCO4C1 is upregulated in MASLD patients, where it serves as a key cAMP transporter dependent on Gln463, suppressing lipogenesis through the PKA-CREB-SREBP1 pathway. Hepatocyte-specific delivery of Slco4c1 via AAV8-TBG increased hepatic cAMP levels, alleviating steatosis, inflammation, and fibrosis in MASLD male mice. Similarly, forskolin, an adenylyl cyclase activator that elevates cAMP, alleviated MASLD progression, underscoring the translational potential of targeting the SLCO4C1-cAMP signaling axis. Mechanistically, during MASLD progression, FGF21 upregulates hepatic Slco4c1 expression through activating ERK/MAPK signaling, which induces EGR1 to directly bind the Slco4c1 promoter, increasing intrahepatic cAMP levels.